Results 61 to 70 of about 243,943 (100)

Regulation of metastatic potential by drug repurposing and mitochondrial targeting in colorectal cancer cells

open access: yesBMC Cancer
Background Increased mitochondrial activities contributing to cancer cell proliferation, invasion, and metastasis have been reported in different cancers; however, studies on the therapeutic targeting of mitochondria in regulating cell proliferation and ...
Shashank Mathur   +7 more
doaj   +1 more source

Solid cancer-directed CAR T cell therapy that attacks both tumor and immunosuppressive cells via targeting PD-L1

open access: yesMolecular Therapy: Oncology
Chimeric antigen receptor (CAR) T cell therapy has encountered limited success in solid tumors. The lack of dependable antigens and the immunosuppressive tumor microenvironment (TME) are major challenges.
Yan Luo   +16 more
doaj   +1 more source

Microstructure and mechanical properties of Haynes 282 superalloy produced by laser powder bed fusion

open access: yesMaterials Today Communications, 2021
A. S. Shaikh   +3 more
semanticscholar   +1 more source

A clinicopathological study about the epidemiology of granulosa cell tumors in Lebanon

open access: yesBMC Cancer
Background Granulosa Cell Tumors (GCT) are considered the most frequent type of sex-cord stromal tumors. These tumors constitute 3-6% of neoplasms of the ovaries. GCTs are divided into 2 types: Juvenile GCT (JGCT) and Adult GCT (AGCT).
Sana Yaacoub, Labib Hajj, Aya Khairallah
doaj   +1 more source

A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal/gastroesophageal junction/proximal gastric adenocarcinoma

open access: yesFrontiers in Oncology
IntroductionEsophageal adenocarcinoma (EAC) remains a devastating disease and second line treatment options in the metastatic space are limited. Homologous recombination (HR) defects have been described in EAC in up to 40% of patients.
Ahmed Bilal Khalid   +7 more
doaj   +1 more source

p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme

open access: yesBMC Cancer
Background Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer, and chemoresistance poses a significant challenge to the survival and prognosis of GBM.
Jiao Meng   +9 more
doaj   +1 more source

Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017

open access: yesThe Lancet, 2018
Gregory A Degu Kalkidan Hassen Solomon M Cristiana Nooshin Roth Abate Abate Abay Abbafati Abbasi Abbastabar A   +499 more
semanticscholar   +1 more source

Understanding the Biological Basis of Polygenic Risk Scores and Disparities in Prostate Cancer: A Comprehensive Genomic Analysis

open access: yesCancer Informatics
Objectives: For prostate cancer (PCa), hundreds of risk variants have been identified. It remains unknown whether the polygenic risk score (PRS) that combines the effects of these variants is also a sufficiently informative metric with relevance to the ...
Wensheng Zhang, Kun Zhang
doaj   +1 more source

Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapy

open access: yesBreast
Background: The majority of HR+/HER2-breast cancer patients can also achieve long-term survival despite not attaining pCR, indicating limited prognostic value of pCR in this population.
Lei Ji   +12 more
doaj   +1 more source

Can we counterbalance restricted access to innovation through specialized breast cancer care? The REAL-NOTE study

open access: yesBreast
Introduction: The KEYNOTE-522 (KN-522) trial showed that the addition of pembrolizumab to standard chemotherapy improved pathological complete response (pCR) and event-free survival (EFS) for patients with early triple negative breast cancer (TNBC).
Leonor Vasconcelos de Matos   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy